A team from The University of British Columbia has used a mechanism-based approach to design irreversible inhibitors of influenza virus neuraminidase. The compounds are being developed by the venture arm of The Centre for Drug Research and Development, a public-private partnership that commercializes discoveries from Canadian researchers.